Sara Johanna K. Malcus Pellmé
Chief Executive Officer bij MetaboGen AB
Profiel
Dr. Sara Johanna K.
Malcus Pellmé is an Independent Director at Vicore Pharma Holding AB and a Managing Director at MetaboGen AB.
She is on the Board of Directors at Vicore Pharma Holding AB.
Dr. Malcus Pellmé was previously employed as a Business Development and Investment Manager by GU Holding AB, a Chief Executive Officer by Ortoma AB, a Project Manager by Arterion AB, a Principal by bioMerieux, Inc., and a Chairman by Oncorena AB.
She also served on the board at Cereno Scientific AB and Oncorena Holding AB.
She received her doctorate degree from the University of Gothenburg.
Actieve functies van Sara Johanna K. Malcus Pellmé
| Bedrijven | Functie | Begin |
|---|---|---|
MetaboGen AB
 MetaboGen AB Internet Software/ServicesTechnology Services MetaboGen AB operates a metagenome and metabolic disease platform. It provides commercial access to metagenome research and development. The firm offers create next generation probiotics and pharmaceutical products, based on the microbiome. The company was founded in 2011 and is headquartered in Göteborg, Sweden. | Chief Executive Officer | 01-01-2015 |
Eerdere bekende functies van Sara Johanna K. Malcus Pellmé
| Bedrijven | Functie | Einde |
|---|---|---|
GU Ventures AB
 GU Ventures AB Investment ManagersFinance GU Ventures AB (GU Ventures) is a venture capital subsidiary of University of Gothenburg founded in 1995. The firm is headquartered in Gothenburg, Sweden. | Private Equity Investor | 31-05-2014 |
| CERENO SCIENTIFIC AB | Director/Board Member | - |
Oncorena Holding AB
 Oncorena Holding AB Pharmaceuticals: MajorHealth Technology Oncorena Holding AB develops novel pharmacological treatment for metastatic renal clear cell cancer. It conducts clinical trial for potential new therapies. The company was founded by Björn Oskar Larsson in 2011 and is headquartered in Helsingborg, Sweden. | Director/Board Member | - |
| VICORE PHARMA HOLDING AB | Director/Board Member | - |
Arterion AB
 Arterion AB BiotechnologyHealth Technology Arterion AB is a holding company that manufactures biomaterials, including artificial blood vessels, consisting of microbial derived cellulose for revascularization of patients with cardiovascular diseases. It focuses on pure uncoated cellulose grafts as replacement of human vessels, primarily as bypass grafts. Its manufacturing method is based on a novel technology that controls the life conditions of the microbe Gluconacetobacter xylinus. Its use of microbial derived cellulose will allow clinicians to use artificial blood vessels as replacement for vessels with an internal diameter of less than five millimeters. The company was founded on January 4, 2007 and is headquartered in Gothenburg, Sweden. | Corporate Officer/Principal | - |
Opleiding van Sara Johanna K. Malcus Pellmé
| University of Gothenburg | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| ORTOMA AB | Health Services |
| VICORE PHARMA HOLDING AB | Health Technology |
| CERENO SCIENTIFIC AB | Health Technology |
| Bedrijven in privébezit | 6 |
|---|---|
bioMérieux, Inc.
 bioMérieux, Inc. Medical SpecialtiesHealth Technology bioMérieux, Inc. develops in-vitro diagnostics solutions. It offers microbiological testing solutions for medical and industrial applications. The company was founded on December 31, 1986 and is headquartered in Durham, NC. | Health Technology |
GU Ventures AB
GU Ventures AB Investment ManagersFinance GU Ventures AB (GU Ventures) is a venture capital subsidiary of University of Gothenburg founded in 1995. The firm is headquartered in Gothenburg, Sweden. | Finance |
Arterion AB
Arterion AB BiotechnologyHealth Technology Arterion AB is a holding company that manufactures biomaterials, including artificial blood vessels, consisting of microbial derived cellulose for revascularization of patients with cardiovascular diseases. It focuses on pure uncoated cellulose grafts as replacement of human vessels, primarily as bypass grafts. Its manufacturing method is based on a novel technology that controls the life conditions of the microbe Gluconacetobacter xylinus. Its use of microbial derived cellulose will allow clinicians to use artificial blood vessels as replacement for vessels with an internal diameter of less than five millimeters. The company was founded on January 4, 2007 and is headquartered in Gothenburg, Sweden. | Health Technology |
MetaboGen AB
MetaboGen AB Internet Software/ServicesTechnology Services MetaboGen AB operates a metagenome and metabolic disease platform. It provides commercial access to metagenome research and development. The firm offers create next generation probiotics and pharmaceutical products, based on the microbiome. The company was founded in 2011 and is headquartered in Göteborg, Sweden. | Technology Services |
Oncorena AB
 Oncorena AB Pharmaceuticals: MajorHealth Technology Oncorena AB develops a novel pharmacological treatment for metastatic renal clear cell cancer. It conducts clinical trial for potential new therapies in humans. The company was founded in 2011 and is headquartered in Helsingborg, Sweden. | Health Technology |
Oncorena Holding AB
Oncorena Holding AB Pharmaceuticals: MajorHealth Technology Oncorena Holding AB develops novel pharmacological treatment for metastatic renal clear cell cancer. It conducts clinical trial for potential new therapies. The company was founded by Björn Oskar Larsson in 2011 and is headquartered in Helsingborg, Sweden. | Health Technology |
